Sarepta Secures FDA Nod For Elevidys Study To Reduce Liver Injury Risk
The U.S. Food and Drug Administration (FDA) on Tuesday approved dosing in Sarepta Therapeutics Inc.'s (NASDAQ: SRPT) Cohort 8 of ENDEAVOR (Study 9001-103).
Fiscal Year: January - December
Sarepta Therapeutics, Inc. (SRPT), listed on the NASDAQ, has a market capitalization of $. As of Dec 07, 2025, the stock is trading at $22.26 per share, offering investors a clear view of its current market value. Sarepta Therapeutics, Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of N/A , investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Sarepta Therapeutics, Inc. also offers a dividend yield of N/A , making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Sarepta Therapeutics, Inc. (SRPT) may be undervalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Sarepta Therapeutics, Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Sarepta Therapeutics, Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Sarepta Therapeutics, Inc. is 0, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Sarepta Therapeutics, Inc. (SRPT) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Sarepta Therapeutics, Inc. (SRPT) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be undervalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Sarepta Therapeutics, Inc. (SRPT) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Sarepta Therapeutics, Inc.. To access the full SS Score, consider upgrading your subscription.
Sarepta Therapeutics, Inc. is a significant player in the industry sector, with a market capitalization of $ and a competitive P/E ratio of N/A . Investors should compare these metrics with industry peers to gauge whether Sarepta Therapeutics, Inc. is outperforming or underperforming within its sector.
The U.S. Food and Drug Administration (FDA) on Tuesday approved dosing in Sarepta Therapeutics Inc.'s (NASDAQ: SRPT) Cohort 8 of ENDEAVOR (Study 9001-103).
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA...
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $200 million milestone payment from Sarepta Therapeutics (NASDAQ: SRPT)...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared progress in the Phase 1/2 multiple ascending dose ...
Intellia Therapeutics and Sarepta Therapeutics have hit serious setbacks potentially linked to their treatments. Both biotechs have lost market value as a result, but both still seem too risky to cons...
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stock jumped on Friday after the FDA issued a new boxed warning for Elevidys. The updated approval follows recent reports of fatal liver injury in non-ambulat...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced an update to the prescribing information for EL...
The U.S. Food and Drug Administration said on Friday it approved new labeling for Sarepta Therapeutics' gene therapy Elevidys that includes its most serious safety warning and restricts use of the tre...
Sarepta Therapeutics, Inc. faces uncertainty after Elevidys' revenue decline and ESSENCE trial failure, leading to a 25% SRPT stock drop. SRPT's PMO franchise remains its cash engine, but regulatory r...
Sarepta Therapeutics Inc. (NASDAQ:SRPT) shared topline data from the ESSENCE Phase 3 trial of Amondys 45 (casimersen) and Vyondys 53 (golodirsen) compared with placebo in 225 patients aged 6-13 years ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stock fell sharply Tuesday following disappointing results from a key clinical trial and ongoing concerns about its drug pipeline. However, "Pharma Bro" Martin...
Sarepta Therapeutics Inc. shares plunged 37% on Tuesday after the biotechnology company reported disappointing trial results for two of its treatments targeting Duchenne muscular dystrophy (DMD). The ...
The biotechnology company discloses disappointing trial data for two treatments for Duchenne muscular dystrophy.
Sarepta Therapeutics, Inc. ( SRPT) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Tamara Thornton Douglas Ingram - CEO & Director Louise Rodino-Klapac - President of Research...
Shares of Sarepta sank 36% before the bell on Tuesday after a trial for two gene-targeted therapies for a muscle-wasting disease missed a key goal, deepening concerns about the company's treatment pip...
Sarepta's stock sank after studies of Duchenne muscular dystrophy treatments failed their primary endpoints.
Sarepta said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not meet the main goal.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter of 2025 ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2025 financial results after the Nasd...
Funds seek to provide 200% long exposure on a variety of industry leaders NEW YORK , Oct. 23, 2025 /PRNewswire/ -- Tradr ETFs, a provider of ETFs designed for sophisticated investors and professional ...
Sarepta Therapeutics is showing signs of recovery, driven by its robust pipeline and recent revenue growth, despite past clinical setbacks. SRPT's near-term catalyst is SRP-9003, a gene therapy for Li...
Sarepta Therapeutics Inc. (NASDAQ:SRPT) stock is trading higher on Wednesday, with apparently no news to justify the movement.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the 30th Annual Congress of the World Muscle So...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on September 30, 2025 (the “Grant Date”) ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced 25 recipients of Route 79, The Duchenne Scholar...
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | # Analysts |
|---|---|---|---|
| 2025 | 8.96M | -102.61% | Est @-102.6% |
| 2026 | 360.67M | 3,924.47% | Analyst x3 |
| 2027 | 405.50M | 12.43% | Analyst x2 |
| 2028 | 422.00M | 4.07% | Analyst x2 |
| 2029 | 383.00M | -9.24% | Analyst x2 |
| 2030 | 367.86M | -3.95% | Est @-4.0% |
| 2031 | 360.39M | -2.03% | Est @-2.0% |
| 2032 | 357.90M | -0.69% | Est @-0.7% |
| 2033 | 358.81M | 0.26% | Est @0.3% |
| 2034 | 361.85M | 0.85% | Est @0.8% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2023A | -577.10M | 1.00 | -577.10M |
| 2024A | -342.74M | 1.00 | -342.74M |
| 2025E | 8.96M | 1.07 | 8.35M |
| 2026E | 360.67M | 1.15 | 313.38M |
| 2027E | 405.50M | 1.23 | 328.43M |
| 2028E | 422.00M | 1.32 | 318.61M |
| 2029E | 383.00M | 1.42 | 269.54M |
| 2030E | 367.86M | 1.52 | 241.32M |
| 2031E | 360.39M | 1.64 | 220.38M |
| 2032E | 357.90M | 1.75 | 204.01M |
| 2033E | 358.81M | 1.88 | 190.65M |
| 2034E | 361.85M | 2.02 | 179.22M |
| Terminal | 7.76B | 2.02 | 3.84B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.